{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T00:11:50Z","timestamp":1649031110617},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1007\/s00105-005-0899-4","type":"journal-article","created":{"date-parts":[[2005,2,7]],"date-time":"2005-02-07T12:53:43Z","timestamp":1107780823000},"page":"241-250","source":"Crossref","is-referenced-by-count":1,"title":["Evidenzbasierte Therapie von Herpes-Virus-Erkrankungen der Haut"],"prefix":"10.1007","volume":"56","author":[{"given":"V.","family":"Mahler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","first-page":"95","volume":"76","author":"ACOG","year":"2002","unstructured":"ACOG practice bulletin (2002) Perinatal viral and parasitic infections. Number 20, September 2000 (Replaces educational bulletin number 177, February 1993). American College of Obstetrics and Gynecologists. Int J Gynaecol Obstet 76:95?107","journal-title":"Int J Gynaecol Obstet"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1128\/AAC.45.10.2771-2774.2001","volume":"45","author":"Acosta","year":"2001","unstructured":"Acosta EP, Balfour HH (2001) Acyclovir for treatment of postherpetic neuralgia: efficacy and pharmacokinetics. Antimicrob Agents Chemother 45:2771?2774","journal-title":"Antimicrob Agents Chemother"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/S0399-077X(98)80098-X","volume":"28","author":"Alfandari","year":"1998","unstructured":"Alfandari S (1998) Second question: antiviral treatment of varicella in adult or immunocompromised patients. Med Malad Infect 28:722?729","journal-title":"Med Malad Infect"},{"key":"CR4","first-page":"255","volume":"49","author":"Alper","year":"2000","unstructured":"Alper BS, Lewis R (2000) Does treatment of acute herpes zoster prevent or shorten postherpetic neuralgia? A systematic review of the literature. J Fam Pract 49:255?264","journal-title":"J Fam Pract"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1097\/00006454-200110000-00002","volume":"20","author":"Balfour","year":"2001","unstructured":"Balfour HH, Edelman CK, Anderson RS et al. (2001) Controlled trial of acyclovir for chickenpox evaluating time of initiation and duration of therapy and viral resistance. Pediatr Infect Dis J 20:919?926","journal-title":"Pediatr Infect Dis J"},{"key":"CR6","first-page":"1609","volume":"134","author":"Bigby","year":"1998","unstructured":"Bigby M (1998) Evidence-based medicine in a nutshell. A guide to finding and using the best evidence in caring for patients. Arch Dermatol 134:1609?1618","journal-title":"Arch Dermatol"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S1085-5629(98)80020-5","volume":"17","author":"Carlton","year":"1998","unstructured":"Carlton S, Evans T, Tyring SK (1998) New antiviral agents for dermatologic disease. Sem Cut Med Surg 17:243?255","journal-title":"Sem Cut Med Surg"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1468-3083.2000.00020.x","volume":"14","author":"Decroix","year":"2000","unstructured":"Decroix J, Partsch H, Gonzalez R et al. (2000) Factors influencing pain outcome in herpes zoster: an observational study with valaciclovir. Valaciclovir International Zoster Assessment Group (VIZA). J Eur Acad Dermatol Venereol 14:23?33","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1001\/jama.1995.03530220066035","volume":"274","author":"Guyatt","year":"1996","unstructured":"Guyatt GH, Sackett DL, Sinclair JC et al. (1996) Users? guides to the medical literature. IX. A method for grading health care recommendations. Evidence-Based Medicine Working Group. JAMA 274:1800?1804","journal-title":"JAMA"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1086\/338832","volume":"185","author":"Harger","year":"2002","unstructured":"Harger JH, Ernest JM, Thurnau GR et al. (2002) Risk factors and outcome of varicella-zoster virus pneumonia in pregnant women. J Infect Dis 185:422?427","journal-title":"J Infect Dis"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"288","DOI":"10.5694\/j.1326-5377.2001.tb143273.x","volume":"174","author":"Heuchan","year":"2001","unstructured":"Heuchan AM, Isaacs D (2001) The management of varicella-zoster virus exposure and infection in pregnancy and the newborn period. Australasian Subgroup in Paediatric Infectious Diseases of the Australasian Society for Infectious Diseases. Med J Aust 174:288?292","journal-title":"Med J Aust"},{"key":"CR12","doi-asserted-by":"crossref","unstructured":"Klassen TP, Belseck EM, Wiebe N, Hartling L (2004) Acyclovir for treating varicella in otherwise healthy children and adolescents. Cochrane Database Syst Rev. 2004 (2):CD002980","DOI":"10.1002\/14651858.CD002980.pub2"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/0264-410X(91)90189-D","volume":"9","author":"Kuter","year":"1991","unstructured":"Kuter BJ, Weibel RE, Guess HA et al. (1991) Oka\/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies. Vaccine 9:643?647","journal-title":"Vaccine"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s001050051346","volume":"52","author":"Mahler","year":"2001","unstructured":"Mahler V, Schuler G (2001) Therapie von Varizella-Zoster- und Herpes-simplex-Virus-bedingten Erkrankungen. Teil 1: Virustatische Agenzien. Hautarzt 52:464?471","journal-title":"Hautarzt"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s001050051346","volume":"52","author":"Mahler","year":"2001","unstructured":"Mahler V, Schuler G (2001) Therapie von Varizella-Zoster- und Herpes-simplex-Virus-bedingten Erkrankungen. Teil 2: Hiweise zur Durchf\u00fchrung und Indikationen zur virustatischen Therapie. Hautarzt 52:554?573","journal-title":"Hautarzt"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0163-4453(98)80153-9","volume":"36","author":"Ogilvie","year":"1998","unstructured":"Ogilvie MM (1998) Antiviral prophylaxis and treatment in chickenpox. A review prepared for the UK Advisory Group on Chickenpox on behalf of the British Society for the Study of Infection. J Infect 36 [Suppl1]:31?38","journal-title":"J Infect"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1056\/NEJM198606123142403","volume":"314","author":"Paryani","year":"1986","unstructured":"Paryani SG, Arvin AM (1986) Intrauterine infection with varicella-zoster virus after maternal varicella. N Engl J Med 314:1542?1546","journal-title":"N Engl J Med"},{"key":"CR18","doi-asserted-by":"crossref","first-page":"754","DOI":"10.2165\/00003495-199652050-00009","volume":"52","author":"Perry","year":"1996","unstructured":"Perry CM, Faulds D (1996) Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs 52:754?772","journal-title":"Drugs"},{"key":"CR19","first-page":"397","volume":"8","author":"Peyramond","year":"1998","unstructured":"Peyramond D, Chidiac C, Lucht F (1998) Management of infections due to the varicella-zoster virus. 11th consensus conference on anti-infectious therapy of the French-speaking Society of Infectious Diseases (SPILF). Eur J Dermatol 8:397?402","journal-title":"Eur J Dermatol"},{"key":"CR20","first-page":"487","volume":"9","author":"Sackett","year":"1993","unstructured":"Sackett D (1993) Rules of evidence and clinical recommendation. Can J Cardiol 9:487?489","journal-title":"Can J Cardiol"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1136\/adc.85.2.83","volume":"85","author":"Skull","year":"2001","unstructured":"Skull SA, Wang EE (2001) Varicella vaccination: a critical review of the evidence. Arch Dis Child 85:83?90","journal-title":"Arch Dis Child"},{"key":"CR22","first-page":"251","volume":"65","author":"Siwek","year":"2002","unstructured":"Siwek J, Gourlay ML, Slawson DC, Shaughnessy AF (2002) How to write an evidence-based clinical review article. Am Fam Physician 65:251?258","journal-title":"Am Fam Physician"},{"key":"CR23","first-page":"261","volume":"32","author":"STIKO","year":"2004","unstructured":"STIKO (2004) Mitteilung der St\u00e4ndigen Impfkommission (STIKO) am Robert Koch Institut. Neues in den aktuellen Impfempfehlungen der STIKO. Epidemiologisches Bulletin 32:261?268","journal-title":"Epidemiologisches Bulletin"},{"key":"CR24","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/bdra.20013","volume":"70","author":"Stone","year":"2004","unstructured":"Stone KM, Reiff-Eldridge R, White AD et al. (2004) Pregnancy outcomes following systemic prenatal acyclovir exposure: Conclusions from the international acyclovir pregnancy registry, 1984?1999. Birth Defects Res A Clin Mol Teratol 70:201?207","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"CR25","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/archfami.9.9.863","volume":"9","author":"Tyring","year":"2000","unstructured":"Tyring SK, Beutner KR, Tucker BA et al. (2000) Antiviral therapy for herpes zoster: Randomised, controlled clinical trial of valaciclovir and famciclovir therapy in immunocompetent patients aged 50 years and older. Arch Fam Med 9:863?869","journal-title":"Arch Fam Med"},{"key":"CR26","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1093\/infdis\/174.Supplement_3.S330","volume":"174","author":"Varis","year":"1996","unstructured":"Varis T, Vesikari T (1996) Efficacy of high-titer live attenuated varicella vaccine in healthy young children. J Infect Dis 174:330?334","journal-title":"J Infect Dis"},{"key":"CR27","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0166-3542(03)00064-0","volume":"59","author":"Wassilew","year":"2003","unstructured":"Wassilew SW, Wutzler P, Brivudin Herpes Zoster Study Group (2003) Oral brivudin in comparison with acyclovir for herpes zoster: a survey study on postherpetic neuralgia. Antiviral Res 59:57?60","journal-title":"Antiviral Res"},{"key":"CR28","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJM198405313102201","volume":"310","author":"Weibel","year":"1984","unstructured":"Weibel RE, Neff BJ, Kuter BJ et al. (1984) Live attenuated varicella virus vaccine. Efficacy trial in healthy children. New Engl J Med 310:1409?1415","journal-title":"New Engl J Med"},{"key":"CR29","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/clinids\/22.2.341","volume":"22","author":"Wood","year":"1996","unstructured":"Wood MJ, Kay R, Dworkin RH et al. (1996) Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster, a meta-analysis of placebo-controlled trials. Clin Infect Dis 22:341?347","journal-title":"Clin Infect Dis"},{"key":"CR30","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1086\/514271","volume":"178","author":"Wood","year":"1998","unstructured":"Wood MJ, Shukla S, Fiddian AO et al. (1998) Treatment of acute herpes zoster: effect of early (<48\u00a0h) versus late (48?72\u00a0h) therapy with acyclovir and valaciclovir on prolonged pain. J Infect Dis 178 [Suppl1]:S81?84","journal-title":"J Infect Dis"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-005-0899-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-005-0899-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-005-0899-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,5]],"date-time":"2020-04-05T17:17:20Z","timestamp":1586107040000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-005-0899-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["899"],"URL":"https:\/\/doi.org\/10.1007\/s00105-005-0899-4","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,3]]}}}